Clinical Scorecard: Breast Cancer Features Following Metabolic and Bariatric Surgery: A Comparative Analysis with Patients Experiencing Severe Obesity
At a Glance
Category
Detail
Condition
Breast cancer in patients with severe obesity, comparing those with and without prior metabolic and bariatric surgery (MBS)
Key Mechanisms
Obesity-related changes in insulin pathways and sex hormone levels influence breast cancer risk; MBS leads to durable weight loss and may reduce breast cancer risk
Target Population
Adult patients (≥18 years) with breast cancer and severe obesity, including those who underwent MBS
Care Setting
Tertiary care center specializing in breast cancer surgery and metabolic/bariatric surgery
Key Highlights
MBS patients had significantly lower BMI at breast cancer surgery compared to non-MBS patients (32.4 vs 38.6 kg/m2, p < 0.0001).
Breast cancer subtypes differed: MBS group had less Luminal A (34.4% vs 59.4%) and more Luminal B (58.6% vs 27.6%) tumors.
No significant difference in disease-free survival, local or systemic recurrence rates, or mortality between MBS and non-MBS groups.
Guideline-Based Recommendations
Diagnosis
Breast cancer diagnosis methods (screening vs mass palpation) showed no significant difference between MBS and non-MBS patients.
Preoperative lymph node biopsy was less frequent in MBS patients (55% vs 76.7%, p = 0.02) but biopsy results were similar.
Management
Type of breast cancer surgery (lumpectomy vs mastectomy) and oncoplastic surgery rates were comparable between groups.
Sentinel lymph node biopsy was more common in MBS patients (79.2% vs 63%, p = 0.09), with no difference in axillary lymph node dissection rates.
No major 30-day postoperative complications were reported in either group.
Monitoring & Follow-up
Disease-free survival and recurrence rates should be monitored similarly in MBS and non-MBS patients, as outcomes were comparable.
Follow-up should include assessment for local and systemic recurrence given similar rates observed.
Risks
No significant difference in postoperative complications or mortality between MBS and non-MBS breast cancer patients.
Ductal carcinoma in situ (DCIS) was significantly higher in non-MBS patients (20% vs 0%, p = 0.03).
Patient & Prescribing Data
Adult women with breast cancer and severe obesity, including those post-MBS
MBS leads to significant weight loss prior to breast cancer surgery but does not significantly alter disease-free survival or recurrence rates compared to non-MBS patients.
Clinical Best Practices
Consider MBS as an effective intervention for severe obesity that may influence breast cancer subtype distribution.
Maintain standard breast cancer diagnostic and surgical management protocols regardless of MBS history.
Monitor breast cancer patients post-MBS with the same vigilance for recurrence and survival outcomes as non-MBS patients.
Recognize that MBS patients may present with different breast cancer receptor profiles, which may impact adjuvant treatment decisions.
